GSK Gives Up On Flagship Cancer Vaccine MAGE-A3

Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer April 2, 2014 GlaxoSmithKline plc today announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer (NSCLC) patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC …

GSK Cancer Vaccine Fails to Meet Phase III Primary Endpoints Again

Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population March 20, 2014 GlaxoSmithKline plc (GSK) today announced that analysis of the MAGRIT trial, a phase …